NewEdge Advisors LLC grew its holdings in Boston Scientific Co. (NYSE:BSX – Free Report) by 34.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 81,307 shares of the medical equipment provider’s stock after buying an additional 20,644 shares during the period. NewEdge Advisors LLC’s holdings in Boston Scientific were worth $6,261,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Eagle Bay Advisors LLC grew its stake in Boston Scientific by 542.1% in the 1st quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 309 shares during the last quarter. First Foundation Advisors bought a new position in shares of Boston Scientific during the first quarter worth approximately $25,000. Triad Wealth Partners LLC bought a new position in shares of Boston Scientific during the second quarter worth approximately $26,000. Andra AP fonden acquired a new stake in Boston Scientific during the 2nd quarter worth approximately $29,000. Finally, RiverPark Advisors LLC bought a new stake in Boston Scientific in the 1st quarter valued at $30,000. 89.07% of the stock is currently owned by institutional investors.
Insider Activity
In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total transaction of $570,511.10. Following the sale, the executive vice president now directly owns 37,468 shares of the company’s stock, valued at approximately $3,061,135.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.50% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on BSX
Boston Scientific Stock Performance
NYSE BSX opened at $84.14 on Wednesday. The firm’s fifty day moving average price is $79.55 and its two-hundred day moving average price is $75.56. The stock has a market cap of $123.44 billion, a PE ratio of 70.71, a PEG ratio of 2.78 and a beta of 0.79. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61. Boston Scientific Co. has a fifty-two week low of $48.35 and a fifty-two week high of $84.89.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.04. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The business had revenue of $4.12 billion during the quarter, compared to analysts’ expectations of $4.02 billion. During the same quarter in the prior year, the firm earned $0.53 EPS. The business’s revenue for the quarter was up 14.5% compared to the same quarter last year. On average, equities analysts expect that Boston Scientific Co. will post 2.4 EPS for the current fiscal year.
Boston Scientific Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Featured Articles
- Five stocks we like better than Boston Scientific
- How to Calculate Inflation Rate
- Why Lennar Stock Could Be the Best Play in the Housing Market
- The 3 Best Blue-Chip Stocks to Buy Now
- 2 Energy Stocks Fueling the AI Datacenter Boom
- How to Read Stock Charts for Beginners
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.